Pieris AG Appoints Chief Scientific Officer - Gilde Healthcare

Pieris AG Appoints Chief Scientific Officer

June 7, 2010

Freising-Weihenstephan – Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development.

“Laurent has an impressive track record of leading teams and moving discovery programs successfully from target identification into and through the clinic. In particular, his pharmacology expertise and drug development skills are the precise ingredients we need to maximize the value of our growing therapeutic pipeline,”

commented Stephen Yoder, CEO of Pieris.

“As the company builds and expands its internal and partnered Anticalin pipeline, Laurent’s contribution will be significant.”

“As a keen proponent of targeted therapeutic technologies, I am excited to join Pieris at a stage where the Anticalin approach is beginning to demonstrate its great therapeutic potential,”

added Dr. Audoly.

“My goal is to combine my experience from big pharma and biotech with the capabilities present at Pieris to bring the full spectrum of R&D operations to the next level.”

Over the course of his career, Dr. Audoly has held research and managerial positions of increasing responsibility, first as Senior Research Scientist, Department of Inflammation, at Pfizer Inc. and then as Senior Research Fellow, Department of Pharmacology, at Merck &Co. Inc. He then joined MedImmune Inc. as Director R&D Inflammation and most recently held the position at Merck and Co. Inc. as Biologics Research Site Lead. He holds a degree in Chemistry from the University of South Florida and a Ph.D. in Pharmacology from Vanderbilt University. Following his studies, he completed post-doctoral research at Duke University and the University of North Carolina. 
 
About Pieris
Pieris AG is an independent biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris’ pipeline ranges from its lead program (anti-VEGF, oncology), which will enter the clinic in the first half of 2010, to multiple Anticalins in preclinical development. Pieris will commercialize Anticalin therapeutics through strategic partnerships, involving both its proprietary pipeline and its de novo drug discovery capabilities. Its most recent partnership is with Allergan, Inc. (NYSE: AGN), focusing on novel treatments for eye diseases.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024